[{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"a6d31c69-7c36-43a0-bc25-c25fb37e0176","acronym":"AGA TKI NSCLC","url":"https://clinicaltrials.gov/study/NCT07158840","created_at":"2025-09-13T08:44:13.914Z","updated_at":"2025-09-13T08:44:13.914Z","phase":"Phase 2","brief_title":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","source_id_and_acronym":"NCT07158840 - AGA TKI NSCLC","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/05/2025","start_date":" 09/05/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-09-08"},{"id":"95dd2ce0-ed59-4a61-b9b8-24f3c51885f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020065","created_at":"2025-06-14T13:53:41.046Z","updated_at":"2025-06-14T13:53:41.046Z","phase":"Phase 2","brief_title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 \u003c50%","source_id_and_acronym":"NCT07020065","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-13"},{"id":"1f0aec53-2934-4132-a061-58ff65518298","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984588","created_at":"2025-09-07T01:41:15.296Z","updated_at":"2025-09-07T01:41:15.296Z","phase":"Phase 2/3","brief_title":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06984588","lead_sponsor":"TJ Biopharma Co., Ltd.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 08/05/2028","primary_completion_date":" 08/05/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-05-22"},{"id":"28d28f42-9a11-470f-aad6-b354ed154518","acronym":"PULMO-01","url":"https://clinicaltrials.gov/study/NCT06879717","created_at":"2025-09-07T02:00:11.544Z","updated_at":"2025-09-07T02:00:11.544Z","phase":"Phase 1/2","brief_title":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06879717 - PULMO-01","lead_sponsor":"iOnctura","biomarkers":" IL7R","pipe":"","alterations":" ","tags":["IL7R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Jemperli (dostarlimab-gxly) • roginolisib (IOA-244)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/22/2025","start_date":" 04/22/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-05-13"},{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"3c07681e-1c58-4557-8010-1fc74e4cbe8d","acronym":"KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596","created_at":"2021-01-19T20:33:04.646Z","updated_at":"2025-02-25T12:27:47.978Z","phase":"Phase 2/3","brief_title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","source_id_and_acronym":"NCT04613596 - KRYSTAL-7","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 806","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 10/31/2028","primary_completion_date":" 10/31/2028","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-02-24"},{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"111c1a17-fe9b-4de2-8802-129cd4e4d500","acronym":"LEAP-006","url":"https://clinicaltrials.gov/study/NCT03829319","created_at":"2021-01-17T17:11:51.730Z","updated_at":"2025-02-25T13:35:12.715Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","source_id_and_acronym":"NCT03829319 - LEAP-006","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 761","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2025-02-21"},{"id":"2dee9945-f549-4f20-8162-2f885a4bbaeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887492","created_at":"2023-06-02T14:06:23.752Z","updated_at":"2025-02-25T13:49:51.075Z","phase":"Phase 1/2","brief_title":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","source_id_and_acronym":"NCT05887492","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • TNG260"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"a672992d-19fb-49b7-9557-516b222cb23a","acronym":"ARTEMIDE-Lung03","url":"https://clinicaltrials.gov/study/NCT06627647","created_at":"2025-02-25T13:36:39.041Z","updated_at":"2025-02-25T13:36:39.041Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","source_id_and_acronym":"NCT06627647 - ARTEMIDE-Lung03","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 878","initiation":"Initiation: 11/27/2024","start_date":" 11/27/2024","primary_txt":" Primary completion: 05/10/2029","primary_completion_date":" 05/10/2029","study_txt":" Completion: 03/25/2030","study_completion_date":" 03/25/2030","last_update_posted":"2025-02-21"},{"id":"09e74a0b-2911-4165-9b8f-e77d19ed6b2f","acronym":"TroFuse-004","url":"https://clinicaltrials.gov/study/NCT06074588","created_at":"2023-10-10T14:11:53.919Z","updated_at":"2025-02-25T13:49:58.239Z","phase":"Phase 3","brief_title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","source_id_and_acronym":"NCT06074588 - TroFuse-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 556","initiation":"Initiation: 11/12/2023","start_date":" 11/12/2023","primary_txt":" Primary completion: 05/10/2027","primary_completion_date":" 05/10/2027","study_txt":" Completion: 03/11/2030","study_completion_date":" 03/11/2030","last_update_posted":"2025-02-20"},{"id":"5b604fcd-b187-4ac2-8cb5-8e6c3fc1616c","acronym":"CheckMate 8KX","url":"https://clinicaltrials.gov/study/NCT03656718","created_at":"2021-01-18T17:56:53.970Z","updated_at":"2025-02-25T13:52:39.029Z","phase":"Phase 1/2","brief_title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","source_id_and_acronym":"NCT03656718 - CheckMate 8KX","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 10/29/2018","start_date":" 10/29/2018","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-20"},{"id":"84e74e03-8f34-4176-b63b-03c06eac53aa","acronym":"CodeBreaK 202","url":"https://clinicaltrials.gov/study/NCT05920356","created_at":"2023-06-27T14:08:07.537Z","updated_at":"2025-02-25T13:55:19.667Z","phase":"Phase 3","brief_title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","source_id_and_acronym":"NCT05920356 - CodeBreaK 202","lead_sponsor":"Amgen","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-02-20"},{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"eb00d46f-58b9-465f-bc29-d7ac0dc998a2","acronym":"Be6A Lung-01","url":"https://clinicaltrials.gov/study/NCT06012435","created_at":"2023-08-25T15:08:41.304Z","updated_at":"2025-02-25T13:55:31.343Z","phase":"Phase 3","brief_title":"A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01).","source_id_and_acronym":"NCT06012435 - Be6A Lung-01","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 02/21/2024","start_date":" 02/21/2024","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2025-02-20"},{"id":"6b56b2f0-6f31-45d1-8ab6-6477c5f17c19","acronym":"RELATIVITY-1093","url":"https://clinicaltrials.gov/study/NCT06561386","created_at":"2025-02-25T14:04:42.242Z","updated_at":"2025-02-25T14:04:42.242Z","phase":"Phase 3","brief_title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","source_id_and_acronym":"NCT06561386 - RELATIVITY-1093","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/07/2024","start_date":" 10/07/2024","primary_txt":" Primary completion: 07/30/2030","primary_completion_date":" 07/30/2030","study_txt":" Completion: 11/11/2033","study_completion_date":" 11/11/2033","last_update_posted":"2025-02-19"},{"id":"6ed2a0a8-e285-495a-88fa-47a7c1d6b11a","acronym":"KeyPemls-004","url":"https://clinicaltrials.gov/study/NCT05599789","created_at":"2022-10-31T13:56:54.671Z","updated_at":"2025-02-25T14:17:21.972Z","phase":"Phase 2","brief_title":"Pembrolizumab in Combination with Plinabulin and Docetaxel for Metastatic NSCLC After ICIs (KeyPemls-004)","source_id_and_acronym":"NCT05599789 - KeyPemls-004","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • plinabulin (BPI 2358)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 01/21/2025","primary_completion_date":" 01/21/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"ca63580a-c74e-4b79-b0d5-8d419247f75b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03177291","created_at":"2021-01-18T15:40:02.831Z","updated_at":"2025-02-25T14:15:00.298Z","phase":"Phase 1","brief_title":"Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC","source_id_and_acronym":"NCT03177291","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/26/2017","start_date":" 09/26/2017","primary_txt":" Primary completion: 05/09/2021","primary_completion_date":" 05/09/2021","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-18"},{"id":"e6419ea6-12ef-460f-8597-b07958498262","acronym":"IMMUNOMEK","url":"https://clinicaltrials.gov/study/NCT05937906","created_at":"2023-07-10T13:08:51.069Z","updated_at":"2025-02-25T14:09:51.533Z","phase":"Phase 1/2","brief_title":"Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003c 50 %.","source_id_and_acronym":"NCT05937906 - IMMUNOMEK","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/30/2024","start_date":" 07/30/2024","primary_txt":" Primary completion: 05/25/2028","primary_completion_date":" 05/25/2028","study_txt":" Completion: 05/25/2028","study_completion_date":" 05/25/2028","last_update_posted":"2025-02-18"},{"id":"acb735f2-e0d3-48ef-9323-330de9633b97","acronym":"BGB-900-102","url":"https://clinicaltrials.gov/study/NCT03744468","created_at":"2021-01-18T18:20:22.768Z","updated_at":"2025-02-25T14:40:03.995Z","phase":"Phase 1/2","brief_title":"Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT03744468 - BGB-900-102","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-14"},{"id":"77b5e130-b913-4feb-83da-546aed463f8e","acronym":"TELMA","url":"https://clinicaltrials.gov/study/NCT03836066","created_at":"2021-01-18T18:56:22.313Z","updated_at":"2025-02-25T15:11:03.613Z","phase":"Phase 2","brief_title":"Atezolizumab Plus Bevacizumab in First Line NSCLC Patients","source_id_and_acronym":"NCT03836066 - TELMA","lead_sponsor":"Fundación GECP","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 10/21/2024","primary_completion_date":" 10/21/2024","study_txt":" Completion: 10/21/2024","study_completion_date":" 10/21/2024","last_update_posted":"2025-02-13"}]